

Appl. No. 09/873,637  
Amdt. Dated October \_\_, 2003  
Reply to Office Action of September 8, 2003

Listing of Claims:

Please cancel claim 23.

Claims 1 – 15 (withdrawn)/

16. (Amended) A method of correlating anti-CRD-BP antibody presence with breast cancer diagnosis ~~determining the presence or absence of anti-CRD-BP antibody in a patient's serum~~ comprising the steps step of:

a) exposing a patient's serum to CRD-BP and determining whether an anti-CRD-BP antibody is present.

b) correlating the presence of anti-CRD-BP antibodies with breast cancer diagnosis.

Claims 17 – 20 (withdrawn).

21. (Previously Added) The method of claim 16 wherein the CRD-BP is recombinant.

22. (Amended) The method of claim 16 wherein the amount of anti-CRD-BP antibody is quantitated.

23. (Amended) The method of claim 16 additionally comprising the step of correlating anti-CRD-BP antibody presence with cancer diagnosis.

Appl. No. 09/873,637  
Amdt. Dated October \_\_, 2003  
Reply to Office Action of September 8, 2003

24. (Previously Added) The method of claim 16 wherein the CRD-BP is bound to a solid support.

25. (Previously Added) The method of claim 24 wherein the CRD-BP is exposed to serum and anti-CRD-BP antibody in the serum binds to the CRD-BP.

*Not further  
OK limit*

26. (Previously Added) The method of claim 16 wherein serum is attached to a solid support.

27. (Previously Added) The method of claim 26 wherein the CRD-BP is radiolabeled and exposed to the serum, wherein the amount of radiolabeled CRD-BP bound to the solid support is measured.